BeStock  
Stocks › Biotechnology › RLAY

Relay Therapeutics RLAY

US equityMarket cap rank #2302Biotechnology
$16.12 +$0.21 (+1.32%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.19 +0.46%
Open$15.59
Prev close$15.91
Day range$15.17 – $16.33
Volume3.98M
Market cap$3.56B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-12.1x
CheapRich

Near the bottom of its 5-year range · 4th percentile, 5-year average -3.6x

Price / book4.9x
CheapRich

Near the top of its 5-year range · 92nd percentile, 5-year average 2.3x

#4358 of 5330 stocks by PB (1 = cheapest)

Price / sales386.2x
CheapRich

Above its usual level · 61st percentile, 5-year average 468.6x

#5048 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-16x-1x14x29xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$20.58
Price vs. fair value-21.7%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 4.88 – 2.34 92% (pricier than usual) #4358 of 5330 (1 = cheapest)
PE -12.06 -11.66 -3.62 4% (cheaper than usual) –
PS 386.20 482.64 468.63 61% (pricier than usual) #5048 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on RLAY.

Sign in to join the discussion.

Scroll to Top